Moreover, the cut-off of each model shows increased sensitivity with reasonable ranges of 95% CI (TIPRL, Sensitivity 46.1%, 95%CI = 40.4–51.9; LC3, Sensitivity 58.1, 95%CI = 52.4–63.7; CD133, Sensitivity 48.8, 95%CI = 37.4–60.2; TIPRL/LC3/CD133, Sensitivity 42.5, 95%CI = 31.5–54.1), thus implying improved diagnostic efficiencies of the TIPRL, LC3, CD133 and TIPRL/LC3/CD133 models in HCCs rather than in a whole population of liver cancers. Here, MAP1LC3A is linked to liver cancer.